RAPT Therapeutics Announces Upcoming Oral Presentation of RPT193 Phase 1b Data at the 4th Inflammatory Skin Disease Summit
October 18 2021 - 8:00AM
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage,
immunology-based biopharmaceutical company focused on
discovering, developing and commercializing oral small molecule
therapies for patients with significant unmet needs in oncology and
inflammatory diseases, today announced that it will present
additional clinical efficacy data from its Phase 1b monotherapy
trial of RPT193 in patients with moderate-to-severe atopic
dermatitis at the 4th Inflammatory Skin Disease Summit to be held
November 3-6, 2021 in New York, NY.
Presentation details as follows:
Title: |
RPT193, an oral CCR4 inhibitor: Efficacy results from a randomized,
placebo-controlled Phase 1b monotherapy trial in patients with
moderate-to-severe atopic dermatitis |
Date & Time: |
November 3, 2021, 5:00 – 5:30 p.m. EST |
Presenter: |
Robert Bissonnette, MD, FRCPC, Chief Executive Officer and Medical
Director of Innovaderm Research Inc. |
About RAPT Therapeutics, Inc.RAPT
Therapeutics is a clinical stage immunology-based biopharmaceutical
company focused on discovering, developing and commercializing oral
small molecule therapies for patients with significant unmet needs
in oncology and inflammatory diseases. Utilizing its proprietary
discovery and development engine, the Company is developing highly
selective small molecules designed to modulate the critical immune
drivers underlying these diseases. RAPT has discovered and advanced
two unique drug candidates, FLX475 and RPT193, each targeting C-C
motif chemokine receptor 4 (CCR4), for the treatment of cancer and
inflammation, respectively. The Company is also pursuing a range of
targets that are in the discovery stage of development.
Forward-Looking StatementsThis press release
contains forward-looking statements. These statements relate to
future events and involve known and unknown risks, uncertainties
and other factors that may cause our actual results, performance or
achievements to be materially different from any future
performances or achievements expressed or implied by the
forward-looking statements. Each of these statements is based only
on current information, assumptions and expectations that are
inherently subject to change and involve a number of risks and
uncertainties. Forward-looking statements include, but are not
limited to, statements about the progress of RAPT’s oncology and
inflammation programs and the interpretation of topline results
from the Phase 1b trial of RPT193. Detailed information regarding
risk factors that may cause actual results to differ materially
from the results expressed or implied by statements in this press
release may be found in RAPT’s Form 10-Q filed with the Securities
and Exchange Commission on August 11, 2021 and subsequent filings
made by RAPT with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date hereof. RAPT
disclaims any obligation to update these forward-looking
statements.
RAPT Media Contact:Aljanae
Reynoldsareynolds@wheelhouselsa.com
RAPT Investor Contact:Sylvia
Wheelerswheeler@wheelhouselsa.com
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Aug 2024 to Sep 2024
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Sep 2023 to Sep 2024